Marker Therapeutics reported earnings of per MRKR share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.12 |
| Last Year's EPS | -$ 0.24 |
| EPS YoY Change |
Out of the last 83 earnings reporting periods, Marker Therapeutics beat analysts’ expectations 28 times and fell short of expectations 9 time(s). Marker Therapeutics reported earnings per share of in the last report surpassing an estimated EPS of -$ 0.12 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.12 | -$ 0.29 | - | |
| Aug 14, 2026 | -$ 0.13 | -$ 0.09 | -$ 0.27 | |
| May 15, 2026 | -$ 0.18 | -$ 0.16 | -$ 0.40 | |
| Mar 18, 2026 | -$ 0.21 | -$ 0.10 | -$ 0.42 | |
| Nov 13, 2025 | -$ 0.36 | -$ 0.12 | -$ 0.26 | |
| Aug 14, 2025 | -$ 0.30 | -$ 0.29 | -$ 0.29 | |
| May 21, 2025 | -$ 0.66 | -$ 0.27 | -$ 0.27 | |
| May 15, 2025 | -$ 0.66 | -$ 0.40 | -$ 0.48 | |
| Mar 31, 2025 | -$ 0.22 | -$ 0.42 | -$ 0.34 | |
| Nov 14, 2024 | -$ 0.39 | -$ 0.26 | -$ 0.47 | |
| Aug 14, 2024 | -$ 0.43 | -$ 0.29 | -$ 0.57 | |
| May 15, 2024 | -$ 0.25 | -$ 0.27 | -$ 0.48 | |
| Mar 26, 2024 | -$ 1.00 | -$ 0.48 | -$ 0.80 | |
| Nov 9, 2023 | -$ 0.90 | -$ 0.34 | -$ 1.10 | |
| Aug 14, 2023 | -$ 0.80 | -$ 0.47 | -$ 1.20 | |
| May 16, 2023 | $ 0.80 | -$ 0.57 | -$ 1.20 | |
| Mar 22, 2023 | -$ 1.00 | -$ 0.48 | -$ 1.20 | |
| Nov 10, 2022 | -$ 1.20 | -$ 0.80 | -$ 1.30 | |
| Aug 11, 2022 | -$ 1.27 | -$ 1.10 | -$ 1.60 | |
| May 13, 2022 | -$ 1.33 | -$ 1.20 | -$ 1.80 |
Marker Therapeutics’s stock was trading at $ 0.9501 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, MRKR’s price decreased to $ 0.87 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | | $ 0.9501 | $ 0.87 | |
| Aug 14, 2026 | -$ 0.09 | $ 1.11 | $ 1.16 | |
| May 15, 2026 | -$ 0.16 | $ 1.46 | $ 1.39 | |
| Mar 18, 2026 | -$ 0.10 | $ 1.36 | $ 1.32 | |
| Nov 13, 2025 | -$ 0.12 | $ 0.9436 | $ 0.923 | |
| Aug 14, 2025 | -$ 0.29 | $ 1.29 | $ 1.26 | |
| May 21, 2025 | -$ 0.27 | $ 1.14 | $ 1.13 | |
| May 15, 2025 | -$ 0.40 | $ 1.12 | $ 1.11 | |
| Mar 31, 2025 | -$ 0.42 | $ 1.27 | $ 1.14 | |
| Nov 14, 2024 | -$ 0.26 | $ 3.64 | $ 3.07 | |
| Aug 14, 2024 | -$ 0.29 | $ 3.39 | $ 3.18 | |
| May 15, 2024 | -$ 0.27 | $ 3.98 | $ 4.10 | |
| Mar 26, 2024 | -$ 0.48 | $ 4.84 | $ 4.34 | |
| Nov 9, 2023 | -$ 0.34 | $ 3.05 | $ 2.73 | |
| Aug 14, 2023 | -$ 0.47 | $ 4.75 | $ 5.86 | |
| May 16, 2023 | -$ 0.57 | $ 1.37 | $ 1.31 | |
| Mar 22, 2023 | -$ 0.48 | $ 1.76 | $ 0.94 | |
| Nov 10, 2022 | -$ 0.80 | $ 3.80 | $ 3.81 | |
| Aug 11, 2022 | -$ 1.10 | $ 4.88 | $ 3.94 | |
| May 13, 2022 | -$ 1.20 | $ 3.14 | $ 3.10 |
Marker Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Marker Therapeutics beat analysts’ expectations during the last earnings period by
